Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Characterization of tumor-infiltrating T lymphocytes expressing PD-1 as a source of anti-tumoral cells for adoptive cell transfer immunotherapy

FY 2019-20

Summary
"Cancer immunotherapy currently shows great promise in the treatment of a growing number of cancers, including melanoma, exploiting the patient's own immune system to fight cancer. A novel immunotherapeutic method involves the transfer of adoptive T cells (ACT) which naturally infiltrate tumors. These cells are expanded ex vivo and reinfused in large number to the patient. This method yields clinical responses in up to 50% of metastatic melanoma patients but is hindered by the low number of tumor-reactive cells in the infused product. We thus propose to elaborate a method to enhance the number of tumor-reactive T cells in the end product. PD-1, a marker of T cell activation, will serve as a marker of T cells having recognized the tumor's neoantigens. Therefore, using a clinical grade sorter, we will demonstrate that selecting PD-1+ TIL enriches the transfusion product in tumor-reactive T cells, and has the potential to enhance ACT. To achieve this, we will characterize and compare the immune features of PD-1+ sorted TIL to the PD-1- sorted TIL and standard bulk expanded TIL, by multi-parametric flow cytometry. We will assess proliferative properties by cell count and CFSE dilutions and T cell clonality by TCR sequencing for each TIL population. Tumors from 6 melanoma patients were excised, sequenced for mutation identification and peptide synthesis and used to generate cell lines, allowing us to assess tumor-specific recognition by performing cocultures of TIL and tumor cell lines or peptide-pulsed B cells, quantified by OX40 and 4-1BB de novo upregulation and IFNγ secretion. We wish to show that the PD-1+ TIL enrichment would represent a suitable approach in the improvement of ACT immunotherapy and will support a clinical trial application to Health Canada."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428676
Name
April William
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of tumor-infiltrating T lymphocytes expressing PD-1 as a source of anti-tumoral cells for adoptive cell transfer immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Cancer Immunotherapy; Cellular Therapy; Clinical-Grade Cell Sorting; Melanoma; Neoantigens; Programmed Cell Death Protein 1; Tumor-Infiltrating Lymphocytes
Abstract
"Cancer immunotherapy currently shows great promise in the treatment of a growing number of cancers, including melanoma, exploiting the patient's own immune system to fight cancer. A novel immunotherapeutic method involves the transfer of adoptive T cells (ACT) which naturally infiltrate tumors. These cells are expanded ex vivo and reinfused in large number to the patient. This method yields clinical responses in up to 50% of metastatic melanoma patients but is hindered by the low number of tumor-reactive cells in the infused product. We thus propose to elaborate a method to enhance the number of tumor-reactive T cells in the end product. PD-1, a marker of T cell activation, will serve as a marker of T cells having recognized the tumor's neoantigens. Therefore, using a clinical grade sorter, we will demonstrate that selecting PD-1+ TIL enriches the transfusion product in tumor-reactive T cells, and has the potential to enhance ACT. To achieve this, we will characterize and compare the immune features of PD-1+ sorted TIL to the PD-1- sorted TIL and standard bulk expanded TIL, by multi-parametric flow cytometry. We will assess proliferative properties by cell count and CFSE dilutions and T cell clonality by TCR sequencing for each TIL population. Tumors from 6 melanoma patients were excised, sequenced for mutation identification and peptide synthesis and used to generate cell lines, allowing us to assess tumor-specific recognition by performing cocultures of TIL and tumor cell lines or peptide-pulsed B cells, quantified by OX40 and 4-1BB de novo upregulation and IFNγ secretion. We wish to show that the PD-1+ TIL enrichment would represent a suitable approach in the improvement of ACT immunotherapy and will support a clinical trial application to Health Canada."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
April, William
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~